This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zamansky & Associates Announces Investigation Of Genoptix, Inc. (GXDX)

Zamansky & Associates (“Zamansky”) has commenced an investigation into Genoptix, Inc. (NASDAQ: GXDX) to determine whether the Company violated federal securities laws by making false and misleading statements regarding its financial condition and prospects.

On May 6, 2010, Genoptix announced its first quarter of 2010 financial results were far below consensus but nevertheless maintained revenue and earnings guidance for 2010. Then, on June 16, 2010, Genoptix issued a press release providing a first look at its second quarter of 2010 performance, and reducing its revenue and earnings guidance for the full year. On this news, Genoptix’s stock fell $5.69 per share to close at $17.19 per share on June 16, 2010, a drop of 25%.

What You May Do

If you have information that would assist Zamansky in its investigation or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail jake@zamansky.com or call (212) 742-1414. Zamansky also encourages anyone with information regarding Genoptix’s conduct during the period from July 31, 2009 and June 15, 2010, to contact the Firm, including whistleblowers, former employees, shareholders, and others.

About Zamansky & Associates

Zamansky & Associates is one of the leading law firms specializing in securities fraud and financial services arbitration and litigation. We represent both individual and institutional investors. Our practice is nationally recognized for our unrivaled ability to aggressively prosecute cases and recover losses.

To learn more about Zamansky, please visit our website,  www.zamansky.com.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs